Celltrion Healthcare Reports Real-World Results Demonstrated Interchangeability of Rituximab Biosimilar
Shots:
- The retrospective observational study published in Internal and Emergency Medicine evaluating patient outcomes after switching from reference rituximab to a biosimilar version (Truxima), showed that transitioning b/w products were safe for patients with no impact on the occurrence of AEs
- No significant differences were seen b/w 2 treatment groups, and no treatment-emergent IRRs of grade 3 or higher were reported in either treatment group. Infections were observed in 33.9% of the biosimilar group vs 35.0% in the rituximab
- Rituximab is used to treat AAV, RA, and SLE on the label, systemic sclerosis, inflammatory myopathies, Sjogren syndrome, and IgG4-related disease off label
Ref: Newswire | Image: Celltrion
Related News:- Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the Health Canada’s Approval for the Treatment of Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
